Titre :

Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.

Auteur(s) :

Costedoat, Ingrid [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Wallaert, Martin [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Gaultier, Aurélie [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Vasseur, Robin [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Vanhaecke, Clelia [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Viguier, Manuelle [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Cordelette, Charles [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Denoyer, Alexandre [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Ferrier Le Bouëdec, Marie-Christine [Auteur]
CHU Clermont-Ferrand
Coutu, Adrien [Auteur]
CHU Clermont-Ferrand
Lamiaux, Marie [Auteur]
Université catholique de Lille [UCL]
Tran, Thi-Ha-Chau [Auteur]
Université catholique de Lille [UCL]
Lacour, Jean-Philippe [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Elmaleh, Valerie [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Tetart, Florence [Auteur]
CHU Rouen
Gueudry, Julie [Auteur]
CHU Rouen
Tauber, Marie [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Giordano-Labadie, Françoise [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Cassagne, Myriam [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Nosbaum, Audrey [Auteur]
Hospices Civils de Lyon [HCL]
Centre International de Recherche en Infectiologie [CIRI]
Ouilhon, Coralie [Auteur]
Centre International de Recherche en Infectiologie [CIRI]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Jachiet, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Tadayoni, Ramin [Auteur]
Hôpital Lariboisière-Fernand-Widal [APHP]
Dezoteux, Frédéric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bouleau, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Labalette, Pierre [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Doan, Serge [Auteur]
CHU Tenon [AP-HP]
Soria, Angele [Auteur]
CHU Tenon [AP-HP]
Mortemousque, Bruno [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Seneschal, Julien [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Barbarot, Sebastien [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]

Titre de la revue :

Journal of the European Academy of Dermatology and Venereology

Nom court de la revue :

J Eur Acad Dermatol Venereol

Date de publication :

2023-02-03

ISSN :

1468-3083

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. ...
Lire la suite >Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T23:24:25Z
2024-03-26T14:16:45Z